Phase II study of AZD0530 in prostate or breast cancer with metastatic bone disease

Phase 2, randomised, open-label trial in prostate cancer (PCa) and breast cancer comparing AZD0530 plus standard of care including zoledronic acid with Standard of care including zoledronic acid alone (2 arms). Primary endpoint: Change in serum βCTX from baseline. Started Dec 2007; status: completed.